SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
22 juil. 2024 08h20 HE
|
SciSparc Ltd
The discovery was demonstrated by utilizing genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors TEL AVIV, Israel, July 22, 2024 (GLOBE NEWSWIRE) -- ...
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
17 juil. 2024 07h07 HE
|
SciSparc Ltd
SciSparc will receive additional payments and execution fees if certain milestones are met TEL AVIV, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or...
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
16 juil. 2024 11h55 HE
|
SciSparc Ltd
TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and...
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
16 juil. 2024 06h03 HE
|
SciSparc Ltd
TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
SciSparc Signs Non-Binding Letter of Intent for Spin Off of Advanced Clinical Stage Pharmaceutical Portfolio to Publicly Traded Company
08 juil. 2024 08h30 HE
|
SciSparc Ltd
According to the agreement, SciSparc’s pharmaceuticals assets are valued at approximately $11.6 million TEL AVIV, Israel, July 08, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC)...
SciSparc Secures Strategic Advantage with Grant of European Patent
31 mai 2024 07h17 HE
|
SciSparc Ltd
TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies...
SciSparc to Acquire AutoMax
11 avr. 2024 08h15 HE
|
SciSparc Ltd
TEL AVIV, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
27 mars 2024 08h55 HE
|
SciSparc Ltd
TEL AVIV, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of...
SciSparc: MitoCareX Unveils Groundbreaking Discovery of Small Molecule Structure in Anti-Cancer Research
21 mars 2024 08h58 HE
|
SciSparc Ltd
MitoCareX Bio dedicates efforts to creating a predictive AI model to predict small molecules more efficiently TEL AVIV, Israel, March 21, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC)...
SciSparc Granted Another Patent, Strengthening its Core Technology in Canada
18 mars 2024 07h29 HE
|
SciSparc Ltd
TEL AVIV, Israel, March 18, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of...